Expand / Collapse search
Watch TV
Menu

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by Refinitiv Lipper.

MEDICAL RESEARCH

Bayer says its drug extends lives of liver cancer patients

By Reuters
Published | Updated
02b16ea7-

The corporate logo of Bayer is seen at the headquarters building in Caracas (Copyright Reuters 2016)

FRANKFURT – Bayer AG said on Thursday its Regorafenib cancer treatment drug helped extend the lives of liver cancer sufferers according to the results of a Phase III clinical trial.

Bayer now plans to file for regulatory approval of the oncology compound, which is also know as Stivarga, it said.

The German company said it plans to submit the data from its study as the basis for marketing authorisation of Regorafenib in the treatment of inoperable liver cancer in 2016.